For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
13
views
3
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      268
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Retraction Note: Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma

      retraction

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Retraction to: Cancer Cell Int (2015) 15:86 DOI 10.1186/s12935-015-0237-6 The Editors-in-Chief and Publisher have retracted this article [1] because the scientific integrity of the content cannot be guaranteed. An investigation by the Publisher found it to be one of a group of articles we have identified as showing evidence suggestive of attempts to subvert the peer review and publication system to inappropriately obtain or allocate authorship. This article showed evidence of plagiarism (most notably from the articles cited [2, 3]) and authorship manipulation.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.

          Hong-Fang Ji, Zhiwei Wang, Hao Zhang … (2013)
          Deregulated microRNAs and their roles in cancer development have attracted much attention. Although miR-133a has been shown to be important in osteogenesis, its roles in osteosarcoma carcinogenesis and progression remain unknown. Hence, we focused on the expression and mechanisms of miR-133a in osteosarcoma development in this study. We found that miR-133a was downregulated in osteosarcoma cell lines and primary human osteosarcoma tissues, and its decrease was significantly correlated with tumor progression and prognosis of the patients. Functional studies revealed that restoration of miR-133a could reduce cell proliferation, promote cell apoptosis, and suppress tumorigenicity in osteosarcoma cell lines. Furthermore, bioinformatic prediction and experimental validation were applied to identify target genes of miR-133a, and the results revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of Bcl-xL and Mcl-1 expression. Taken together, our data elucidate the roles of miR-133a in osteosarcoma pathogenesis and implicate its potential in cancer therapy. Crown Copyright © 2013. Published by Elsevier Inc. All rights reserved.
          Article 0 comments Cited 72 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma

            Alireza Mirghasemi, Afshin Taheriazam, Seyyed Hasan Karbasy … (2015)
            Background MicroRNAs (miRNAs) play key roles in cancer development and progression. The purpose of the present study was to determine the expression levels of miR-133a and miR-539 in osteosarcoma patients and to further investigate the clinicopathological, and prognostic value of these miRNAs. Methods The expression levels of miR-133a and miR-539 were determined by qRT-PCR. Associations between miRNAs expressions and various clinicopathological characteristics were analyzed. Survival rate was determined with Kaplan–Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysis Results Our findings revealed that the miR-133a expression was significantly decreased in clinical osteosarcoma tissues compared to adjacent normal bone tissues. The expression level of miR-539 was decreased in clinical osteosarcoma tissues as compared to those adjacent normal tissues. Low expressions of miR-133a and miR-539 were significantly association with advanced TNM stage (P = 0.002; P = 0.001), and metastasis or recurrence (P = 0.001; P = 0.01). Furthermore, Kaplan–Meier survival analysis and log-rank test showed that the low expressions of miR-133a and miR-539 were correlated with the reduced overall survival of osteosarcoma patients. Multivariate Cox proportional hazards model showed that decreased expressions of miR-133a and miR-539 (P = 0.007; P = 0.02), TNM stage (P = 0.001; P = 0.002), and metastasis or recurrence (P = 0.005; P = 0.026) were independent prognostic markers of overall survival of patients. Conclusion These results suggest that decreased miR-133a and miR-539 expressions may participate in the progression of osteosarcoma. Together, these results showed that miR-133a and miR-539 may have their role in both progression and prognosis of osteosarcoma.
            Article 0 comments Cited 16 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Downregulation of miR-133b/miR-503 acts as efficient prognostic and diagnostic factors in patients with osteosarcoma and these predictor biomarkers are correlated with overall survival

              SA Bassampour, R Abdi, R Bahador … (2015)
              Article 0 comments Cited 3 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Aram Mokarizadeh: a.mokarizadeh@muk.ac.ir
                Journal
                Journal ID (nlm-ta): Cancer Cell Int
                Journal ID (iso-abbrev): Cancer Cell Int
                Title: Cancer Cell International
                Publisher: BioMed Central (London )
                ISSN (Electronic): 1475-2867
                Publication date (Electronic): 4 November 2016
                Publication date PMC-release: 4 November 2016
                Publication date Collection: 2016
                Volume: 16
                Electronic Location Identifier: 84
                Affiliations
                [1 ]Department of Orthopedics, Qom University of Medical Sciences, Qom, Iran
                [2 ]Department of Orthopedics Surgery, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
                [3 ]Department of Anesthesiology, Birjand University of Medical Sciences, Birjand, Iran
                [4 ]Department of Orthopedics, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
                [5 ]Department of Orthopaedic and Trauma Surgery, Birjand University of Medical Sciences, Birjand, Iran
                [6 ]Department of Molecular Biology, Baqiyatallah University of Medical Sciences, Tehran, Iran
                [7 ]Cellular & Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
                Article
                Publisher ID: 359
                DOI: 10.1186/s12935-016-0359-5
                PMC ID: 5096315
                PubMed ID: 27822140
                SO-VID: 7ffaef2e-cc2b-40ef-b5b0-90c76440fa61
                Copyright © © The Author(s) 2016
                License:

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                Date received : 20 October 2016
                Date accepted : 20 October 2016
                Related
                Categories
                Subject: Retraction Note
                Custom metadata
                issue-copyright-statement © The Author(s) 2016

                ScienceOpen disciplines: Oncology & Radiotherapy
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy

                Comments

                Comment on this article

                scite_

                Similar content268

                See all similar

                Cited by3

                See all cited by

                Most referenced authors36

                See all reference authors